ArticleThe Journal of infection2023

Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase.

Eric Yuk Fai Wan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.